Hematology Program
Smilow Cancer Hospital at Yale New Haven
35 Park Street
New Haven, CT 06511
- Hematology ProgramSmilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511
Lourdes Mendez, MD, PhD
Hematology, Hematologic Oncology
Telehealth is available
Patient type treated
Adult
Accepting new patients
Yes
Referral required
Not Applicable
Board Certified in
Hematology (Internal Medicine)
Biography
Lourdes Mendez, MD, PhD, is a hematologic oncologist specializing in the treatment of leukemia, particularly acute lymphoblastic leukemia.
As an assistant professor at Yale School of Medicine, Dr. Mendez is involved in research that seeks to develop new therapeutic options for leukemia and myeloid disorders (a group of blood cancers that affect the bone marrow’s ability to produce healthy blood cells). Her research aims to translate laboratory findings into clinical applications to enhance patient care.
Dr. Mendez received her medical training from Albert Einstein College of Medicine and completed her residency at Weill Cornell-New York Presbyterian. She pursued a fellowship in hematology and oncology at Beth Israel Deaconess Medical Center, where she also completed a postdoctoral fellowship in cancer genetics.
Titles
- Assistant Professor
Education & Training
- Research FellowBeth Israel Deaconess Medical Center (2017)
- Clinical Fellow in Hematology/OncologyBeth Israel Deaconess Medical Center (2014)
- ResidentWeill Cornell-New York Presbyterian (2011)
- InternWeill Cornell-New York Presbyterian (2009)
- PhDAlbert Einstein College of Medicine, Cell Biology
- MDAlbert Einstein College of Medicine
Languages Spoken
- English
- Español (Spanish)
Additional Information
Board Certifications
- AB of Internal Medicine, Hematology (Internal Medicine) (2014)
Professional Service
- American Society of Hematology (2007 - Present): Member
Publications
- Alhajahjeh A, Woite N, Rolles B, Stempel J, Mina A, Mendez L, Kewan T, Podoltsev N, Stahl M, Grimshaw A, Zeidan A, Bewersdorf J. Luspatercept for patients with lower-risk myelodysplastic syndromes/neoplasms: a systematic review and meta-analysis. Blood Advances 2025, 9: 6511-6523. PMID: 40966428, DOI: 10.1182/bloodadvances.2025017611.
- Hunter C, Chou A, Roeder H, Eighmy W, Bewersdorf J, Mendez L, Stahl M, Podoltsev N, Zeidan A, Shallis R. Isavuconazole provides effective and tolerable antifungal prophylaxis for patients with acute myeloid leukemia. Leukemia Research 2025, 160: 108144. PMID: 41365214, DOI: 10.1016/j.leukres.2025.108144.
- Taborda C, Gong G, Douglas G, Liu J, Incoom A, Stahl M, Podoltsev N, Bewersdorf J, Getz T, Stempel J, Kewan T, Lanino L, Bidikian A, Parker T, Bar N, Browning S, Halene S, Neparidze N, Zeidan A, Mendez L. Prospective evaluation of an AI-powered clinical trial patient matching (CTPM) system in myelodysplastic syndromes (MDS) and multiple myeloma. Blood 2025, 146: 1086-1086. DOI: 10.1182/blood-2025-1086.
- Hunter C, Chetlapalli K, Ito S, Bewersdorf J, Boddu P, Browning S, Halene S, Parker T, Huntington S, Kothari S, Mendez L, Neparidze N, Sethi T, Stahl M, Podoltsev N, Zeidan A, Shallis R, Goshua G. Early discharge program cost savings for patients with newly diagnosed acute myeloid leukemia after intensive induction chemotherapy. Blood 2025, 146: 6208. DOI: 10.1182/blood-2025-6208.
- Lanino L, Getz T, Kewan T, Kiwan A, Rolles B, Bidikian A, Sariipek N, Mendez L, Podoltsev N, Durant T, Meeker D, Perincheri S, Gershkovich P, Katz S, Siddon A, Xu M, Bewersdorf J, Della Porta M, Zeidan A, Stahl M. Large language models mediated extraction of clinical information from bone marrow biopsy pathology reports. Blood 2025, 146: 2555. DOI: 10.1182/blood-2025-2555.
- Bewersdorf J, Wang R, Mendez L, Stahl M, Zeidan A, Ma X, Podoltsev N. Acute myeloid leukemia (AML) after myeloproliferative neoplasm (MPN): Real-world outcomes in the new AML treatment era. Blood 2025, 146: 721. DOI: 10.1182/blood-2025-721.
- Katkov D, Mendez L, Podoltsev N, Stahl M, Zeidan A, Bewersdorf J. Clinical characteristics, disease progression, and vascular events in essential thrombocythemia: A single-center cohort study with long-term follow-up. Blood 2025, 146: 7322. DOI: 10.1182/blood-2025-7322.
- Wang R, Stempel J, Shallis R, Bewersdorf J, Mendez L, Stahl M, Zeidan A, Ma X, Podoltsev N. Treatment initiation and first line tyrosine kinase inhibitor (TKI) selection for older patients with newly diagnosed chronic myeloid leukemia (CML) in the United States (US) before and after the introduction of generic imatinib (GE-IMA). Blood 2025, 146: 6393-6393. DOI: 10.1182/blood-2025-6393.
- Stempel J, Wang R, Shallis R, Mendez L, Bewersdorf J, Stahl M, Zeidan A, Ma X, Podoltsev N. Impact of metformin on the incidence of thrombotic events in older patients with polycythemia vera and essential thrombocythemia in the United States. Blood 2025, 146: 6392-6392. DOI: 10.1182/blood-2025-6392.
- Stahl M, Bewersdorf J, Vedula R, Liu Y, Murdock H, Tsai H, Chen E, Rolles B, Podoltsev N, Mendez L, Lanino L, Mina A, Aguirre L, Sekeres M, Ades L, Lindsley R, Zeidan A. Validation of the international working group (IWG) 2023 criteria for clinical benefit in higher risk Myelodysplastic Syndromes (HR-MDS) using a large, international, randomized Phase 3 clinical trial dataset. Blood 2025, 146: 5651. DOI: 10.1182/blood-2025-5651.
- Bidikian A, Al-Musa A, Hunter C, Mendez L, Podoltsev N, Stahl M, Zeidan A, Shallis R, Bewersdorf J. Clinical, cytogenetic and molecular predictors of early mortality in acute promyelocytic leukemia (APL): Real-world analysis. Blood 2025, 146: 5160-5160. DOI: 10.1182/blood-2025-5160.
- Beke K, Alhajahjeh A, Grimshaw A, Podoltsev N, Mendez L, Stahl M, Zeidan A, Bewersdorf J. Menin inhibitors for NPM1-mutated and KMT2A-rearranged relapsed/refractory acute myeloid leukemia (AML): A systematic review and meta-analysis. Blood 2025, 146: 5154-5154. DOI: 10.1182/blood-2025-5154.
- Chen E, Liu Y, Stein E, Ball B, Gojo I, Odenike O, Palmisiano N, Duong V, Gong Z, Hochman M, Bossard C, Hill J, Grifman M, Deangelo D, Stone R, Galinsky I, Leonard R, Little R, Gore S, Bewersdorf J, Mendez L, Podoltsev N, Zeidan A, Abdel-Wahab O, Stahl M. Trial in progress: A phase I study evaluating the safety of cirtuvivint (CIRT) as monotherapy and in combination with ASTX727 in patients with myelodysplastic syndromes (MDS) and Acute Myeloid Leukemia (AML). Blood 2025, 146: 3431-3431. DOI: 10.1182/blood-2025-3431.
- Bhardwaj P, Baassiri A, Sundaram R, Friedman S, Elia J, Kiwan A, Matthews M, VanOudenhove J, Mendez L, Gueble S, Bindra R, Halene S. MGMT-silencing as a novel biomarker in AML: Rational application of a dual alkylator-DNA crosslinker for targeted therapy. Blood 2025, 146: 322-322. DOI: 10.1182/blood-2025-322.
- Hunter C, Cheng W, Bewersdorf J, Boddu P, Browning S, Halene S, Parker T, Huntington S, Kothari S, Mendez L, Neparidze N, Sethi T, Barbarotta L, Podoltsev N, Zeidan A, Shallis R. Feasibility, safety and outcomes of patients with newly diagnosed acute myeloid leukemia discharged ‘early’ after intensive induction. Leukemia & Lymphoma 2025, ahead-of-print: 1-12. PMID: 41160735, DOI: 10.1080/10428194.2025.2578420.
- Author Correction: An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancerChen M, Zhang J, Sampieri K, Clohessy J, Mendez L, Gonzalez-Billalabeitia E, Liu X, Lee Y, Fung J, Katon J, Menon A, Webster K, Ng C, Palumbieri M, Diolombi M, Breitkopf S, Teruya-Feldstein J, Signoretti S, Bronson R, Asara J, Castillo-Martin M, Cordon-Cardo C, Pandolfi P. Author Correction: An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer. Nature Genetics 2025, 57: 2931-2931. PMID: 41125873, DOI: 10.1038/s41588-025-02394-w.
- Alhajahjeh A, Patel K, Podoltsev N, Kewan T, Stempel J, Mendez L, Seropian S, Gowda L, Huntington S, Stahl M, Zeidan A, Goshua G, Bewersdorf J. Cost-effectiveness of upfront vs delayed allogeneic hematopoietic stem cell transplant for intermediate risk AML. Blood Advances 2025, 9: 5234-5246. PMID: 40720773, PMCID: PMC12550792, DOI: 10.1182/bloodadvances.2025016532.
- Wang R, Stempel J, Shallis R, Huntington S, Zeidan A, Neparidze N, Di M, Bewersdorf J, Mendez L, Ma X, Podoltsev N. Second malignancies among older patients with classical myeloproliferative neoplasms treated with ruxolitinib. Blood Neoplasia 2025, 2: 100159. PMID: 41216598, PMCID: PMC12597058, DOI: 10.1016/j.bneo.2025.100159.
- Bewersdorf J, Hasle V, Shallis R, Thompson E, de Menezes D, Rose S, Boss I, Mendez L, Podoltsev N, Stahl M, Kewan T, Halene S, Haferlach T, Fox B, Zeidan A. Integrated Immune Landscape Analysis of RNA Splicing Factor-Mutant AML and Higher risk MDS Treated with Azacitidine ± Durvalumab. Therapeutic Advances In Hematology 2025, 16: 20406207251347344. PMID: 40546817, PMCID: PMC12182606, DOI: 10.1177/20406207251347344.
- Alhajahjeh A, Woite N, Grimshaw A, Rolles B, Stahl M, Kewan T, Podoltsev N, Stempel J, Mendez L, Zeidan A, Bewersdorf J. Luspatercept in patients with lower-risk myelodysplastic syndromes (MDS): A systematic review and meta-analysis. Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e18574.
- Yang M, Boye-Doe A, Ali M, Abosabie S, Barr A, Mendez L, Sharda A. RalB uncoupling from exocyst is required for endothelial Weibel-Palade body exocytosis. Molecular Biology Of The Cell 2025, 36: ar62. PMID: 40172988, PMCID: PMC12086567, DOI: 10.1091/mbc.e24-11-0493.
- Alhajahjeh A, Patel K, Shallis R, Podoltsev N, Kewan T, Stempel J, Mendez L, Huntington S, Stahl M, Goshua G, Bewersdorf J, Zeidan A. Cost-effectiveness of Enasidenib versus conventional care for older patients with IDH2-mutant refractory/relapsed AML. Leukemia & Lymphoma 2024, 66: 488-496. PMID: 39560957, PMCID: PMC12138910, DOI: 10.1080/10428194.2024.2426073.
- A review of the isocitrate dehydrogenase inhibitors in management of adult patients with AML and MDSNorman M, Yamartino K, Gerstein R, Shallis R, Mendez L, Podoltsev N, Stahl M, Eighmy W, Zeidan A. A review of the isocitrate dehydrogenase inhibitors in management of adult patients with AML and MDS. Expert Review Of Hematology 2024, 17: 755-767. PMID: 39474840, DOI: 10.1080/17474086.2024.2422554.
- Diolombi M, Sharda A, Chen M, Sejour L, Bester A, Nachmani D, Clohessy J, Pandolfi P, Mendez L. Ppara Deletion Promotes Monocytic Leukemia Granulocytic Differentiation. Blood 2024, 144: 4118. DOI: 10.1182/blood-2024-211508.
- Kewan T, Ladel L, Kiwan A, Mendez L. ETV6 Mutations in Myeloid Neoplasia: Unraveling Clinical Features and Molecular Signatures. Blood 2024, 144: 4582-4582. DOI: 10.1182/blood-2024-211479.
- Abosabie S, Mendez L, Sharda A. Phenotypic and Transcriptomic Profiling of MPN Endothelium. Blood 2024, 144: 1228. DOI: 10.1182/blood-2024-211468.
- Hunter C, Bewersdorf J, Mendez L, Podoltsev N, Zeidan A, Eighmy W, Roeder H, Malinis M, Shallis R. Risk Factors and Predictors of Outcomes after Invasive Fungal Infection Among Patients with Acute Myeloid Leukemia. Blood 2024, 144: 4253. DOI: 10.1182/blood-2024-211426.
- Hunter C, Bewersdorf J, Mendez L, Podoltsev N, Zeidan A, Eighmy W, Roeder H, Malinis M, Shallis R. Toxicity and Efficacy of Isavuconazole Vs Voriconazole As Anti-Fungal Prophylaxis for Patients with Acute Myeloid Leukemia. Blood 2024, 144: 1480-1480. DOI: 10.1182/blood-2024-211250.
- Impact of Sepsis and Stress Hematopoiesis on the Acquisition and Persistence of Clonal HematopoiesisOgbue O, Kewan T, Unlu S, Lakhotiya K, Mehkri O, Ellison R, Fadell F, Reynolds M, Cheema A, Durmaz A, Brady Z, VanOudenhove J, Singh A, Visconte V, Mendez L, Bosler D, Duggal A, Halene S, Al-Jaghbeer M, Maciejewski J, Gurnari C. Impact of Sepsis and Stress Hematopoiesis on the Acquisition and Persistence of Clonal Hematopoiesis. Blood 2024, 144: 5634-5634. DOI: 10.1182/blood-2024-209240.
- Potnis K, Ito S, Patel K, Shallis R, Podoltsev N, Kewan T, Stempel J, Mendez L, Huntington S, Stahl M, Zeidan A, Bewersdorf J, Goshua G. Cost-Effectiveness of Eltrombopag Plus Immunosuppressive Therapy Versus Immunosuppressive Therapy Alone in Adults with Severe Aplastic Anemia in the United States. Blood 2024, 144: 3644. DOI: 10.1182/blood-2024-204312.
- Alhajahjeh A, Patel K, Shallis R, Podoltsev N, Kewan T, Stempel J, Mendez L, Huntington S, Stahl M, Zeidan A, Goshua G, Bewersdorf J. Cost-Effectiveness of Allogeneic Hematopoietic Stem Cell Transplantation Versus Consolidation Chemotherapy for Patients with Intermediate Risk Acute Myeloid Leukemia. Blood 2024, 144: 788. DOI: 10.1182/blood-2024-201535.
- Brunner A, Liu Y, Garcia J, Mendez L, Gutierrez C, Amrein P, Narayan R, Vedula R, Neuberg D, Andrade-Campos M, Smith S, Stone R, Fathi A, Walter M, Graubert T, Jacoby M. Clinical Activity and Safety of the Oral ATR Inhibitor Ceralasertib (AZD6738) in Patients with MDS or CMML after Prior HMA Therapy. Blood 2024, 144: 1833-1833. DOI: 10.1182/blood-2024-195793.
- Alhajahjeh A, Rotter L, Stempel J, Grimshaw A, Bewersdorf J, Blaha O, Kewan T, Podoltsev N, Shallis R, Mendez L, Stahl M, Zeidan A. Global Disparities in the Characteristics and Outcomes of Leukemia Clinical Trials: A Cross-Sectional Study of the ClinicalTrials.gov Database. JCO Global Oncology 2024, 10: e2400316. PMID: 39621951, DOI: 10.1200/go-24-00316.
- Rotter L, Alhajahjeh A, Stempel J, Grimshaw A, Bewersdorf J, Blaha O, Kewan T, Podoltsev N, Shallis R, Mendez L, Stahl M, Zeidan A. Analyzing determinants of premature trial discontinuation in leukemia clinical trials. Leukemia & Lymphoma 2024, 66: 289-297. PMID: 39440622, DOI: 10.1080/10428194.2024.2416565.
- Xie Z, Komrokji R, Al Ali N, Regelson A, Geyer S, Patel A, Saygin C, Zeidan A, Bewersdorf J, Mendez L, Kishtagari A, Zeidner J, Coombs C, Madanat Y, Chung S, Badar T, Foran J, Desai P, Tsai C, Griffiths E, Al Malki M, Amanam I, Lai C, Deeg H, Ades L, Arana Yi C, Osman A, Dinner S, Abaza Y, Taylor J, Chandhok N, Soong D, Brunner A, Carraway H, Singh A, Elena C, Ferrari J, Gallì A, Pozzi S, Padron E, Patnaik M, Malcovati L, Savona M, Al-Kali A. Risk prediction for clonal cytopenia: multicenter real-world evidence. Blood 2024, 144: 2033-2044. PMID: 38996210, PMCID: PMC11561536, DOI: 10.1182/blood.2024024756.
- Taborda C, Zeidan A, Mendez L. Clonal cytopenia of undetermined significance: definitions, risk and therapeutic targets. Frontiers In Hematology 2024, 3: 1419323. DOI: 10.3389/frhem.2024.1419323.
- Bewersdorf J, Patel K, Shallis R, Podoltsev N, Kewan T, Stempel J, Mendez L, Stahl M, Stein E, Huntington S, Goshua G, Zeidan A. Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3-mutant acute myeloid leukemia. Leukemia & Lymphoma 2024, 65: 1136-1144. PMID: 38648559, PMCID: PMC11265977, DOI: 10.1080/10428194.2024.2344052.
- Yang M, Mendez L, Sharda A. Ralb and Exocyst Regulate Endothelial Cell Von Willebrand Factor Release. Blood 2023, 142: 501. DOI: 10.1182/blood-2023-189635.
- Shallis R, Wang R, Zeidan A, Huntington S, Neparidze N, Stempel J, Mendez L, Di M, Ma X, Podoltsev N. Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence. Blood Advances 2023, 7: 3213-3224. PMID: 36939371, PMCID: PMC10338212, DOI: 10.1182/bloodadvances.2022009074.
- Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid NeoplasmsXie Z, Chen E, Mendez L, Komrokji R, Zeidan A. Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms. The Cancer Journal 2023, 29: 130-137. PMID: 37195768, DOI: 10.1097/ppo.0000000000000656.
- Mendez L, Patnaik M. Clonal Hematopoiesis: Origins and determinants of evolution. Leukemia Research 2023, 129: 107076. PMID: 37075557, DOI: 10.1016/j.leukres.2023.107076.
- VanOudenhove J, Halene S, Mendez L. Is it the time to integrate novel sequencing technologies into clinical practice? Current Opinion In Hematology 2022, 30: 70-77. PMID: 36602939, DOI: 10.1097/moh.0000000000000754.
- Daver N, Montesinos P, Aribi A, Marconi G, Altman J, Wang E, Roboz G, Burke P, Gaidano G, Walter R, Thomas X, Jeyakumar D, DeAngelo D, Erba H, Todisco E, Begna K, Advani A, Gastaud L, De La Fuente A, Curti A, Mendez L, Vyas P, Boissel N, Vey N, Recher C, Longval T, Platzbecker U, Kapp-Schwoerer S, Schliemann C, Konopleva M, Torres L, Sallman D, Marcucci G, Pemmaraju N, Martinelli G, Kantarjian H, Sloss C, Malcolm K, Zweidler-McKay P, Sweet K. Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML). Blood 2022, 140: 145-149. DOI: 10.1182/blood-2022-158030.
- Garcia J, Flamand Y, Penter L, Keng M, Tomlinson B, Mendez L, Koller P, Cullen N, Arihara Y, Pfaff K, Wolff J, Brunner A, Galinsky I, Bashey A, Antin J, Cutler C, Ho V, Jonas B, Luskin M, Wadleigh M, Winer E, Savell A, Leonard R, Robertson T, Davids M, Streicher H, Rodig S, Ritz J, Wu C, DeAngelo D, Neuberg D, Stone R, Soiffer R. Ipilimumab plus decitabine for patients with MDS or AML in post-transplant or transplant naïve settings. Blood 2022, 141: 1884-1888. PMID: 36332187, PMCID: PMC10122101, DOI: 10.1182/blood.2022017686.
- Daver N, Montesinos P, Aribi A, Martinelli G, Altman J, Wang E, Roboz G, Burke P, Gaidano G, Walter R, Thomas X, Jeyakumar D, DeAngelo D, Erba H, Todisco E, Begna K, Advani A, Gastaud L, de la Fuente A, Curti A, Mendez L, Vyas P, Boissel N, Vey N, Recher C, Longval T, Platzbecker U, Kapp-Schwörer S, Schliemann C, Konopleva M, Torres L, Sallman D, Marcucci G, Marconi G, Kantarjian H, Sloss C, Malcolm K, Zweidler-McKay P, Sweet K. AML-262 Pivekimab Sunirine (PVEK, IMGN632) Triplet With Azacitidine and Venetoclax Shows Broad Activity in Adverse Genetic Subsets of Relapsed/Refractory Acute Myeloid Leukemia and Reduced Infusion-Related Reactions. Clinical Lymphoma Myeloma & Leukemia 2022, 22: s231-s232. DOI: 10.1016/s2152-2650(22)01257-5.
- Daver N, Montesinos P, Aribi A, Martinelli G, Altman J, Wang E, Roboz G, Burke P, Gaidano G, Walter R, Thomas X, Jeyakumar D, DeAngelo D, Erba H, Todisco E, Begna K, Advani A, Gastaud L, de la Fuente A, Curti A, Mendez L, Vyas P, Boissel N, Vey N, Recher C, Longval T, Platzbecker U, Kapp-Schwörer S, Schliemann C, Konopleva M, Torres L, Sallman D, Marcucci G, Marconi G, Kantarjian H, Sloss C, Malcolm K, Zweidler-McKay P, Sweet K. Poster: AML-262 Pivekimab Sunirine (PVEK, IMGN632) Triplet With Azacitidine and Venetoclax Shows Broad Activity in Adverse Genetic Subsets of Relapsed/Refractory Acute Myeloid Leukemia and Reduced Infusion-Related Reactions. Clinical Lymphoma Myeloma & Leukemia 2022, 22: s132. DOI: 10.1016/s2152-2650(22)00792-3.
- Brunner A, Liu Y, Mendez L, Garcia J, Amrein P, Neuberg D, Dean E, Smith S, Stone R, Fathi A, Walter M, Graubert T, Jacoby M. P758: INHIBITION OF ATR WITH CERALASERTIB (AZD6738) FOR THE TREATMENT OF PROGRESSIVE OR RELAPSED MYELODYSPLASTIC SYNDROMES AND CHRONIC MYELOMONOCYTIC LEUKEMIA: A PHASE IB/II STUDY. HemaSphere 2022, 6: 653-654. DOI: 10.1097/01.hs9.0000845916.12740.98.
- Liegel J, Bindal P, Stone R, Soiffer R, Stroopinsky D, Cheloni G, Bisharat L, Torres D, Rahimian M, Yoo S, Logan E, Elavalakanar P, Banna H, Hauser J, Koshy A, Ho V, Romee R, Neuberg D, Liu Y, Mendez L, Dias A, Ebert B, Kufe D, Avigan D, Rosenblatt J. 158 Post-Transplant Vaccination with a Personalized Dendritic Cell/AML Fusion Cell Vaccine for Prevention of Relapse. Transplantation And Cellular Therapy 2022, 28: s129-s130. DOI: 10.1016/s2666-6367(22)00319-0.
- Liegel J, Bindal P, Stone R, Soiffer R, Stroopinsky D, Cheloni G, Bisharat L, Torres D, Rahimian M, Yoo S, Logan E, Elavalakanar P, Banna H, Hauser J, Koshy A, Romee R, Ho V, Neuberg D, Liu Y, Mendez L, Dias A, Ebert B, Kufe D, Avigan D, Rosenblatt J. Post-Transplant Vaccination with a Personalized Dendritic Cell/AML Fusion Cell Vaccine for Prevention of Relapse. Blood 2021, 138: 2830. DOI: 10.1182/blood-2021-154166.
- Luskin M, Stevenson K, Mendez L, Wang E, Wadleigh M, Garcia J, Stone R, An H, Hagopian E, Galinsky I, Rae L, Leonard R, DeAngelo D, Murakami M. A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for BCR-ABL1-Positive ALL in Adults. Blood 2021, 138: 2305. DOI: 10.1182/blood-2021-149225.
- Brunner A, Liu Y, Mendez L, Garcia J, Amrein P, Neuberg D, Dean E, Smith S, Stone R, Fathi A, Walter M, Graubert T, Jacoby M. Inhibition of ATR with AZD6738 (Ceralasertib) for the Treatment of Progressive or Relapsed Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: Safety and Preliminary Activity from a Phase Ib/II Study. Blood 2021, 138: 1521. DOI: 10.1182/blood-2021-147301.
- Daver N, Aribi A, Montesinos P, Roboz G, Wang E, Walter R, Jeyakumar D, DeAngelo D, Erba H, Advani A, Burke P, Martinelli G, Gastaud L, Thomas X, Altman J, Mendez L, de la Fuente A, Todisco E, Gaidano G, Curti A, Boissel N, Recher C, Schliemann C, Sloss C, Wang J, Malcolm K, Zweidler-McKay P, Sweet K. A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMGN632 As Monotherapy or in Combination with Venetoclax and Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia. Blood 2021, 138: 4440. DOI: 10.1182/blood-2021-146585.
- Daver N, Aribi A, Montesinos P, Roboz G, Wang E, Walter R, Jeyakumar D, DeAngelo D, Erba H, Advani A, Burke P, Martinelli G, Gastaud L, Thomas X, Altman J, Mendez L, de la Fuente A, Todisco E, Gaidano G, Curti A, Boissel N, Recher C, Schliemann C, Konopleva M, Sallman D, Torres L, Marcucci G, Kantarjian H, Sloss C, Malcolm K, Zweidler-McKay P, Sweet K. Safety and Efficacy from a Phase 1b/2 Study of IMGN632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia. Blood 2021, 138: 372. DOI: 10.1182/blood-2021-146503.
- Kukkula A, Ojala V, Mendez L, Sistonen L, Elenius K, Sundvall M. Therapeutic Potential of Targeting the SUMO Pathway in Cancer. Cancers 2021, 13: 4402. PMID: 34503213, PMCID: PMC8431684, DOI: 10.3390/cancers13174402.
- Sharda A, Bogue T, Barr A, Mendez L, Flaumenhaft R, Zwicker J. Circulating Protein Disulfide Isomerase Is Associated with Increased Risk of Thrombosis in JAK2-Mutated Myeloproliferative NeoplasmsPlasma PDI and Thrombosis in MPN. Clinical Cancer Research 2021, 27: 5708-5717. PMID: 34400417, PMCID: PMC9170286, DOI: 10.1158/1078-0432.ccr-21-1140.
- . VWF maturation and release are controlled by 2 regulators of Weibel-Palade body biogenesis: exocyst and BLOC-2. Blood 2020, 136: 2824-2837. PMID: 32614949, PMCID: PMC7731791, DOI: 10.1182/blood.2020005300.
- Nachmani D, Mendez L, Pandolfi P. Aberrant rRNA 2′-O-Methylation Causes Bone Marrow Failure and Defective Immune Function. Blood 2020, 136: 11-12. DOI: 10.1182/blood-2020-141809.
- Liegel J, Stone R, Soiffer R, Stroopinsky D, Bisharat L, Rahimian M, Logan E, Elavalakanar P, Ho V, Romee R, Neuberg D, Liu Y, Mendez L, Dias A, Bindal P, Koshy A, Orr S, Torres D, Cheloni G, Ebert B, Kufe D, Avigan D, Rosenblatt J. Vaccination with a Personalized Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in a Phase 1 Clinical Trial. Blood 2020, 136: 10. DOI: 10.1182/blood-2020-141634.
- Garcia J, Flamand Y, Tomlinson B, Keng M, Mendez L, Khaled S, Bashey A, Brunner A, Savell A, Neuberg D, Galinsky I, Luskin M, Steensma D, Wadleigh M, Winer E, Avigan D, Cullen N, Rodig S, Penter L, Lindsley R, Andrews S, Davids M, Wu C, Stone R, DeAngelo D, Soiffer R. Safety and Efficacy of Decitabine Plus Ipilimumab in Relapsed or Refractory MDS/AML in the Post-BMT or Transplant Naïve Settings. Blood 2020, 136: 15-17. DOI: 10.1182/blood-2020-136235.
- Brunner A, Blonquist T, DeAngelo D, McMasters M, Fell G, Hermance N, Winer E, Lindsley R, Hobbs G, Amrein P, Hock H, Steensma D, Garcia J, Luskin M, Stone R, Ballen K, Rosenblatt J, Avigan D, Nahas M, Mendez L, McAfee S, Moran J, Bergeron M, Foster J, Bertoli C, Manning A, McGregor K, Fishman K, Kuo F, Baltay M, Macrae M, Burke M, Behnan T, Wey M, Som T, Ramos A, Rae J, Lombardi Story J, Nelson N, Logan E, Connolly C, Neuberg D, Chen Y, Graubert T, Fathi A. Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. The Lancet Haematology 2019, 7: e122-e133. PMID: 31837959, PMCID: PMC10354959, DOI: 10.1016/s2352-3026(19)30203-0.
- Sharda A, Harrison J, Wilkie A, Fang C, Mendez L, Italiano J, Flaumenhaft R. VWF Exocytosis and Biogenesis of Weibel Palade Bodies in Endothelial Cells Are Differentially Controlled By Interactions between Bloc-2 and the Exocyst Complex. Blood 2019, 134: 8. DOI: 10.1182/blood-2019-127712.
- . The Interplay Between the Genetic and Immune Landscapes of AML: Mechanisms and Implications for Risk Stratification and Therapy. Frontiers In Oncology 2019, 9: 1162. PMID: 31781488, PMCID: PMC6856667, DOI: 10.3389/fonc.2019.01162.
- . Germline NPM1 mutations lead to altered rRNA 2′-O-methylation and cause dyskeratosis congenita. Nature Genetics 2019, 51: 1518-1529. PMID: 31570891, PMCID: PMC6858547, DOI: 10.1038/s41588-019-0502-z.
- . Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy. Cell Research 2019, 29: 446-459. PMID: 31024166, PMCID: PMC6796925, DOI: 10.1038/s41422-019-0162-7.
- Liegel J, Stroopinsky D, Mendez L, McMasters M, Ghiasuddin H, Rahimian M, Nahas M, Weinstock M, Jain S, Capelletti M, Bisharat L, Morin A, Orr S, Rosenblatt J, Kufe D, Avigan D. Ex-Vivo Stimulation with DC/AML Fusion Vaccine in the Presence of Cytokines Leads to an Activated T Cell Memory Phenotype and Enhanced Cytotoxicity with Potential for Use As an Adoptive Cellular Therapy. Blood 2018, 132: 2728. DOI: 10.1182/blood-2018-99-119996.
- . Deregulated PP1α phosphatase activity towards MAPK activation is antagonized by a tumor suppressive failsafe mechanism. Nature Communications 2018, 9: 159. PMID: 29335436, PMCID: PMC5768788, DOI: 10.1038/s41467-017-02272-y.
- . An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer. Nature Genetics 2018, 50: 206-218. PMID: 29335545, PMCID: PMC6714980, DOI: 10.1038/s41588-017-0027-2.
- . A non-cell-autonomous role for Pml in the maintenance of leukemia from the niche. Nature Communications 2018, 9: 66. PMID: 29302031, PMCID: PMC5754357, DOI: 10.1038/s41467-017-02427-x.
- Mendez L, Chen M, Pandolfi P. Molecular Genetics of APL. 2017, 41-53. DOI: 10.1007/978-3-319-64257-4_4.
- Pyzer AR, Stroopinsky D, Rosenblatt J, Anastasiadou E, Rajabi H, Washington A, Tagde A, Chu JH, Coll M, Jiao AL, Tsai LT, Tenen DE, Cole L, Palmer K, Ephraim A, Leaf RK, Nahas M, Apel A, Bar-Natan M, Jain S, McMasters M, Mendez L, Arnason J, Raby BA, Slack F, Kufe D, Avigan D. MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs. Leukemia 2017, 31: 2780-2790. PMID: 28555079, PMCID: PMC5791150, DOI: 10.1038/leu.2017.163.
- Pyzer A, Stroopinsky D, Rajabi H, Washington A, Tagde A, Coll M, Fung J, Bryant M, Cole L, Palmer K, Somaiya P, Karp Leaf R, Nahas M, Apel A, Jain S, McMasters M, Mendez L, Levine J, Joyce R, Arnason J, Pandolfi P, Kufe D, Rosenblatt J, Avigan D. MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia. Blood 2017, 129: 1791-1801. PMID: 28126925, PMCID: PMC5813734, DOI: 10.1182/blood-2016-07-730614.
- Mendez L, Sharda A, Zwicker J. Thrombophilia and Thrombocytopenia in the Pregnant Woman. 2017, 55-76. DOI: 10.1007/978-3-319-39328-5_4.
- Molecular Genetics of Acute Promyelocytic LeukemiaMendez LM, Chen M, Pandolfi PP. Molecular Genetics of Acute Promyelocytic Leukemia. In: Abla, Oussama, Lo Coco, Francesco, Sanz, Miguel A, editors. Acute Promyelocytic Leukemia. Springer 2018.
- Mendez L, Sharda A, Bodio K, Joyce R. PET/CT in lymphoma surveillance: A large single-center experience. Journal Of Clinical Oncology 2014, 32: 8569-8569. DOI: 10.1200/jco.2014.32.15_suppl.8569.
- Thrombophilia and Thrombocytopenia in the Pregnant WomanMendez LM, Sharda AV, Zwicker JI. Thrombophilia and Thrombocytopenia in the Pregnant Woman. In: Bernstein C, Takoudes T, editors. Medical Problems During Pregnancy. Springer: 2017
- Arnason J, Mendez L. Induction Therapy for Gamma-Heavy Chain Disease with Bortezomib and Dexamethasone: A Case Report. Blood 2012, 120: 5051. DOI: 10.1182/blood.v120.21.5051.5051.
- Cerchietti LC, Hatzi K, Caldas-Lopes E, Yang SN, Figueroa ME, Morin RD, Hirst M, Mendez L, Shaknovich R, Cole PA, Bhalla K, Gascoyne RD, Marra M, Chiosis G, Melnick A. BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy. J Clin Invest 2010, 120: 4569-82. PMID: 21041953, DOI: 10.1172/JCI42869.
- Mendez LM, Polo JM, Yu JJ, Krupski M, Ding BB, Melnick A, Ye BH. CtBP is an essential corepressor for BCL6 autoregulation. Mol Cell Biol 2008, 28: 2175-86. PMID: 18212045, DOI: 10.1128/MCB.01400-07.
- Ding BB, Yu JJ, Yu RY, Mendez LM, Shaknovich R, Zhang Y, Cattoretti G, Ye BH. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 2008, 111: 1515-23. PMID: 17951530, DOI: 10.1182/blood-2007-04-087734.
- Wang X, Ding BB, Mendez LM, Papetti M, Ye BH. Re: Torlakovic et al. PU.1 protein expression has a positive linear association with protein expression of germinal centre B cell genes including BCL-6, CD10, CD20 and CD22: identification of PU.1 putative binding sites in the BCL-6 promotor. J Pathol 2005;206:312-319. J Pathol 2006, 210: 130-1; author reply 132. PMID: 16841370, DOI: 10.1002/path.2031.
Departments and Programs
Locations
Hematology Program
Smilow Cancer Hospital at Yale New Haven
35 Park Street
New Haven, CT 06511
- Hematology ProgramSmilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511
Biography
Lourdes Mendez, MD, PhD, is a hematologic oncologist specializing in the treatment of leukemia, particularly acute lymphoblastic leukemia.
As an assistant professor at Yale School of Medicine, Dr. Mendez is involved in research that seeks to develop new therapeutic options for leukemia and myeloid disorders (a group of blood cancers that affect the bone marrow’s ability to produce healthy blood cells). Her research aims to translate laboratory findings into clinical applications to enhance patient care.
Dr. Mendez received her medical training from Albert Einstein College of Medicine and completed her residency at Weill Cornell-New York Presbyterian. She pursued a fellowship in hematology and oncology at Beth Israel Deaconess Medical Center, where she also completed a postdoctoral fellowship in cancer genetics.
Titles
- Assistant Professor
Education & Training
- Research FellowBeth Israel Deaconess Medical Center (2017)
- Clinical Fellow in Hematology/OncologyBeth Israel Deaconess Medical Center (2014)
- ResidentWeill Cornell-New York Presbyterian (2011)
- InternWeill Cornell-New York Presbyterian (2009)
- PhDAlbert Einstein College of Medicine, Cell Biology
- MDAlbert Einstein College of Medicine
Languages Spoken
- English
- Español (Spanish)
Additional Information
Board Certifications
- AB of Internal Medicine, Hematology (Internal Medicine) (2014)
Professional Service
- American Society of Hematology (2007 - Present): Member
Publications
- Alhajahjeh A, Woite N, Rolles B, Stempel J, Mina A, Mendez L, Kewan T, Podoltsev N, Stahl M, Grimshaw A, Zeidan A, Bewersdorf J. Luspatercept for patients with lower-risk myelodysplastic syndromes/neoplasms: a systematic review and meta-analysis. Blood Advances 2025, 9: 6511-6523. PMID: 40966428, DOI: 10.1182/bloodadvances.2025017611.
- Hunter C, Chou A, Roeder H, Eighmy W, Bewersdorf J, Mendez L, Stahl M, Podoltsev N, Zeidan A, Shallis R. Isavuconazole provides effective and tolerable antifungal prophylaxis for patients with acute myeloid leukemia. Leukemia Research 2025, 160: 108144. PMID: 41365214, DOI: 10.1016/j.leukres.2025.108144.
- Taborda C, Gong G, Douglas G, Liu J, Incoom A, Stahl M, Podoltsev N, Bewersdorf J, Getz T, Stempel J, Kewan T, Lanino L, Bidikian A, Parker T, Bar N, Browning S, Halene S, Neparidze N, Zeidan A, Mendez L. Prospective evaluation of an AI-powered clinical trial patient matching (CTPM) system in myelodysplastic syndromes (MDS) and multiple myeloma. Blood 2025, 146: 1086-1086. DOI: 10.1182/blood-2025-1086.
- Hunter C, Chetlapalli K, Ito S, Bewersdorf J, Boddu P, Browning S, Halene S, Parker T, Huntington S, Kothari S, Mendez L, Neparidze N, Sethi T, Stahl M, Podoltsev N, Zeidan A, Shallis R, Goshua G. Early discharge program cost savings for patients with newly diagnosed acute myeloid leukemia after intensive induction chemotherapy. Blood 2025, 146: 6208. DOI: 10.1182/blood-2025-6208.
- Lanino L, Getz T, Kewan T, Kiwan A, Rolles B, Bidikian A, Sariipek N, Mendez L, Podoltsev N, Durant T, Meeker D, Perincheri S, Gershkovich P, Katz S, Siddon A, Xu M, Bewersdorf J, Della Porta M, Zeidan A, Stahl M. Large language models mediated extraction of clinical information from bone marrow biopsy pathology reports. Blood 2025, 146: 2555. DOI: 10.1182/blood-2025-2555.
- Bewersdorf J, Wang R, Mendez L, Stahl M, Zeidan A, Ma X, Podoltsev N. Acute myeloid leukemia (AML) after myeloproliferative neoplasm (MPN): Real-world outcomes in the new AML treatment era. Blood 2025, 146: 721. DOI: 10.1182/blood-2025-721.
- Katkov D, Mendez L, Podoltsev N, Stahl M, Zeidan A, Bewersdorf J. Clinical characteristics, disease progression, and vascular events in essential thrombocythemia: A single-center cohort study with long-term follow-up. Blood 2025, 146: 7322. DOI: 10.1182/blood-2025-7322.
- Wang R, Stempel J, Shallis R, Bewersdorf J, Mendez L, Stahl M, Zeidan A, Ma X, Podoltsev N. Treatment initiation and first line tyrosine kinase inhibitor (TKI) selection for older patients with newly diagnosed chronic myeloid leukemia (CML) in the United States (US) before and after the introduction of generic imatinib (GE-IMA). Blood 2025, 146: 6393-6393. DOI: 10.1182/blood-2025-6393.
- Stempel J, Wang R, Shallis R, Mendez L, Bewersdorf J, Stahl M, Zeidan A, Ma X, Podoltsev N. Impact of metformin on the incidence of thrombotic events in older patients with polycythemia vera and essential thrombocythemia in the United States. Blood 2025, 146: 6392-6392. DOI: 10.1182/blood-2025-6392.
- Stahl M, Bewersdorf J, Vedula R, Liu Y, Murdock H, Tsai H, Chen E, Rolles B, Podoltsev N, Mendez L, Lanino L, Mina A, Aguirre L, Sekeres M, Ades L, Lindsley R, Zeidan A. Validation of the international working group (IWG) 2023 criteria for clinical benefit in higher risk Myelodysplastic Syndromes (HR-MDS) using a large, international, randomized Phase 3 clinical trial dataset. Blood 2025, 146: 5651. DOI: 10.1182/blood-2025-5651.
- Bidikian A, Al-Musa A, Hunter C, Mendez L, Podoltsev N, Stahl M, Zeidan A, Shallis R, Bewersdorf J. Clinical, cytogenetic and molecular predictors of early mortality in acute promyelocytic leukemia (APL): Real-world analysis. Blood 2025, 146: 5160-5160. DOI: 10.1182/blood-2025-5160.
- Beke K, Alhajahjeh A, Grimshaw A, Podoltsev N, Mendez L, Stahl M, Zeidan A, Bewersdorf J. Menin inhibitors for NPM1-mutated and KMT2A-rearranged relapsed/refractory acute myeloid leukemia (AML): A systematic review and meta-analysis. Blood 2025, 146: 5154-5154. DOI: 10.1182/blood-2025-5154.
- Chen E, Liu Y, Stein E, Ball B, Gojo I, Odenike O, Palmisiano N, Duong V, Gong Z, Hochman M, Bossard C, Hill J, Grifman M, Deangelo D, Stone R, Galinsky I, Leonard R, Little R, Gore S, Bewersdorf J, Mendez L, Podoltsev N, Zeidan A, Abdel-Wahab O, Stahl M. Trial in progress: A phase I study evaluating the safety of cirtuvivint (CIRT) as monotherapy and in combination with ASTX727 in patients with myelodysplastic syndromes (MDS) and Acute Myeloid Leukemia (AML). Blood 2025, 146: 3431-3431. DOI: 10.1182/blood-2025-3431.
- Bhardwaj P, Baassiri A, Sundaram R, Friedman S, Elia J, Kiwan A, Matthews M, VanOudenhove J, Mendez L, Gueble S, Bindra R, Halene S. MGMT-silencing as a novel biomarker in AML: Rational application of a dual alkylator-DNA crosslinker for targeted therapy. Blood 2025, 146: 322-322. DOI: 10.1182/blood-2025-322.
- Hunter C, Cheng W, Bewersdorf J, Boddu P, Browning S, Halene S, Parker T, Huntington S, Kothari S, Mendez L, Neparidze N, Sethi T, Barbarotta L, Podoltsev N, Zeidan A, Shallis R. Feasibility, safety and outcomes of patients with newly diagnosed acute myeloid leukemia discharged ‘early’ after intensive induction. Leukemia & Lymphoma 2025, ahead-of-print: 1-12. PMID: 41160735, DOI: 10.1080/10428194.2025.2578420.
- Author Correction: An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancerChen M, Zhang J, Sampieri K, Clohessy J, Mendez L, Gonzalez-Billalabeitia E, Liu X, Lee Y, Fung J, Katon J, Menon A, Webster K, Ng C, Palumbieri M, Diolombi M, Breitkopf S, Teruya-Feldstein J, Signoretti S, Bronson R, Asara J, Castillo-Martin M, Cordon-Cardo C, Pandolfi P. Author Correction: An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer. Nature Genetics 2025, 57: 2931-2931. PMID: 41125873, DOI: 10.1038/s41588-025-02394-w.
- Alhajahjeh A, Patel K, Podoltsev N, Kewan T, Stempel J, Mendez L, Seropian S, Gowda L, Huntington S, Stahl M, Zeidan A, Goshua G, Bewersdorf J. Cost-effectiveness of upfront vs delayed allogeneic hematopoietic stem cell transplant for intermediate risk AML. Blood Advances 2025, 9: 5234-5246. PMID: 40720773, PMCID: PMC12550792, DOI: 10.1182/bloodadvances.2025016532.
- Wang R, Stempel J, Shallis R, Huntington S, Zeidan A, Neparidze N, Di M, Bewersdorf J, Mendez L, Ma X, Podoltsev N. Second malignancies among older patients with classical myeloproliferative neoplasms treated with ruxolitinib. Blood Neoplasia 2025, 2: 100159. PMID: 41216598, PMCID: PMC12597058, DOI: 10.1016/j.bneo.2025.100159.
- Bewersdorf J, Hasle V, Shallis R, Thompson E, de Menezes D, Rose S, Boss I, Mendez L, Podoltsev N, Stahl M, Kewan T, Halene S, Haferlach T, Fox B, Zeidan A. Integrated Immune Landscape Analysis of RNA Splicing Factor-Mutant AML and Higher risk MDS Treated with Azacitidine ± Durvalumab. Therapeutic Advances In Hematology 2025, 16: 20406207251347344. PMID: 40546817, PMCID: PMC12182606, DOI: 10.1177/20406207251347344.
- Alhajahjeh A, Woite N, Grimshaw A, Rolles B, Stahl M, Kewan T, Podoltsev N, Stempel J, Mendez L, Zeidan A, Bewersdorf J. Luspatercept in patients with lower-risk myelodysplastic syndromes (MDS): A systematic review and meta-analysis. Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e18574.
- Yang M, Boye-Doe A, Ali M, Abosabie S, Barr A, Mendez L, Sharda A. RalB uncoupling from exocyst is required for endothelial Weibel-Palade body exocytosis. Molecular Biology Of The Cell 2025, 36: ar62. PMID: 40172988, PMCID: PMC12086567, DOI: 10.1091/mbc.e24-11-0493.
- Alhajahjeh A, Patel K, Shallis R, Podoltsev N, Kewan T, Stempel J, Mendez L, Huntington S, Stahl M, Goshua G, Bewersdorf J, Zeidan A. Cost-effectiveness of Enasidenib versus conventional care for older patients with IDH2-mutant refractory/relapsed AML. Leukemia & Lymphoma 2024, 66: 488-496. PMID: 39560957, PMCID: PMC12138910, DOI: 10.1080/10428194.2024.2426073.
- A review of the isocitrate dehydrogenase inhibitors in management of adult patients with AML and MDSNorman M, Yamartino K, Gerstein R, Shallis R, Mendez L, Podoltsev N, Stahl M, Eighmy W, Zeidan A. A review of the isocitrate dehydrogenase inhibitors in management of adult patients with AML and MDS. Expert Review Of Hematology 2024, 17: 755-767. PMID: 39474840, DOI: 10.1080/17474086.2024.2422554.
- Diolombi M, Sharda A, Chen M, Sejour L, Bester A, Nachmani D, Clohessy J, Pandolfi P, Mendez L. Ppara Deletion Promotes Monocytic Leukemia Granulocytic Differentiation. Blood 2024, 144: 4118. DOI: 10.1182/blood-2024-211508.
- Kewan T, Ladel L, Kiwan A, Mendez L. ETV6 Mutations in Myeloid Neoplasia: Unraveling Clinical Features and Molecular Signatures. Blood 2024, 144: 4582-4582. DOI: 10.1182/blood-2024-211479.
- Abosabie S, Mendez L, Sharda A. Phenotypic and Transcriptomic Profiling of MPN Endothelium. Blood 2024, 144: 1228. DOI: 10.1182/blood-2024-211468.
- Hunter C, Bewersdorf J, Mendez L, Podoltsev N, Zeidan A, Eighmy W, Roeder H, Malinis M, Shallis R. Risk Factors and Predictors of Outcomes after Invasive Fungal Infection Among Patients with Acute Myeloid Leukemia. Blood 2024, 144: 4253. DOI: 10.1182/blood-2024-211426.
- Hunter C, Bewersdorf J, Mendez L, Podoltsev N, Zeidan A, Eighmy W, Roeder H, Malinis M, Shallis R. Toxicity and Efficacy of Isavuconazole Vs Voriconazole As Anti-Fungal Prophylaxis for Patients with Acute Myeloid Leukemia. Blood 2024, 144: 1480-1480. DOI: 10.1182/blood-2024-211250.
- Impact of Sepsis and Stress Hematopoiesis on the Acquisition and Persistence of Clonal HematopoiesisOgbue O, Kewan T, Unlu S, Lakhotiya K, Mehkri O, Ellison R, Fadell F, Reynolds M, Cheema A, Durmaz A, Brady Z, VanOudenhove J, Singh A, Visconte V, Mendez L, Bosler D, Duggal A, Halene S, Al-Jaghbeer M, Maciejewski J, Gurnari C. Impact of Sepsis and Stress Hematopoiesis on the Acquisition and Persistence of Clonal Hematopoiesis. Blood 2024, 144: 5634-5634. DOI: 10.1182/blood-2024-209240.
- Potnis K, Ito S, Patel K, Shallis R, Podoltsev N, Kewan T, Stempel J, Mendez L, Huntington S, Stahl M, Zeidan A, Bewersdorf J, Goshua G. Cost-Effectiveness of Eltrombopag Plus Immunosuppressive Therapy Versus Immunosuppressive Therapy Alone in Adults with Severe Aplastic Anemia in the United States. Blood 2024, 144: 3644. DOI: 10.1182/blood-2024-204312.
- Alhajahjeh A, Patel K, Shallis R, Podoltsev N, Kewan T, Stempel J, Mendez L, Huntington S, Stahl M, Zeidan A, Goshua G, Bewersdorf J. Cost-Effectiveness of Allogeneic Hematopoietic Stem Cell Transplantation Versus Consolidation Chemotherapy for Patients with Intermediate Risk Acute Myeloid Leukemia. Blood 2024, 144: 788. DOI: 10.1182/blood-2024-201535.
- Brunner A, Liu Y, Garcia J, Mendez L, Gutierrez C, Amrein P, Narayan R, Vedula R, Neuberg D, Andrade-Campos M, Smith S, Stone R, Fathi A, Walter M, Graubert T, Jacoby M. Clinical Activity and Safety of the Oral ATR Inhibitor Ceralasertib (AZD6738) in Patients with MDS or CMML after Prior HMA Therapy. Blood 2024, 144: 1833-1833. DOI: 10.1182/blood-2024-195793.
- Alhajahjeh A, Rotter L, Stempel J, Grimshaw A, Bewersdorf J, Blaha O, Kewan T, Podoltsev N, Shallis R, Mendez L, Stahl M, Zeidan A. Global Disparities in the Characteristics and Outcomes of Leukemia Clinical Trials: A Cross-Sectional Study of the ClinicalTrials.gov Database. JCO Global Oncology 2024, 10: e2400316. PMID: 39621951, DOI: 10.1200/go-24-00316.
- Rotter L, Alhajahjeh A, Stempel J, Grimshaw A, Bewersdorf J, Blaha O, Kewan T, Podoltsev N, Shallis R, Mendez L, Stahl M, Zeidan A. Analyzing determinants of premature trial discontinuation in leukemia clinical trials. Leukemia & Lymphoma 2024, 66: 289-297. PMID: 39440622, DOI: 10.1080/10428194.2024.2416565.
- Xie Z, Komrokji R, Al Ali N, Regelson A, Geyer S, Patel A, Saygin C, Zeidan A, Bewersdorf J, Mendez L, Kishtagari A, Zeidner J, Coombs C, Madanat Y, Chung S, Badar T, Foran J, Desai P, Tsai C, Griffiths E, Al Malki M, Amanam I, Lai C, Deeg H, Ades L, Arana Yi C, Osman A, Dinner S, Abaza Y, Taylor J, Chandhok N, Soong D, Brunner A, Carraway H, Singh A, Elena C, Ferrari J, Gallì A, Pozzi S, Padron E, Patnaik M, Malcovati L, Savona M, Al-Kali A. Risk prediction for clonal cytopenia: multicenter real-world evidence. Blood 2024, 144: 2033-2044. PMID: 38996210, PMCID: PMC11561536, DOI: 10.1182/blood.2024024756.
- Taborda C, Zeidan A, Mendez L. Clonal cytopenia of undetermined significance: definitions, risk and therapeutic targets. Frontiers In Hematology 2024, 3: 1419323. DOI: 10.3389/frhem.2024.1419323.
- Bewersdorf J, Patel K, Shallis R, Podoltsev N, Kewan T, Stempel J, Mendez L, Stahl M, Stein E, Huntington S, Goshua G, Zeidan A. Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3-mutant acute myeloid leukemia. Leukemia & Lymphoma 2024, 65: 1136-1144. PMID: 38648559, PMCID: PMC11265977, DOI: 10.1080/10428194.2024.2344052.
- Yang M, Mendez L, Sharda A. Ralb and Exocyst Regulate Endothelial Cell Von Willebrand Factor Release. Blood 2023, 142: 501. DOI: 10.1182/blood-2023-189635.
- Shallis R, Wang R, Zeidan A, Huntington S, Neparidze N, Stempel J, Mendez L, Di M, Ma X, Podoltsev N. Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence. Blood Advances 2023, 7: 3213-3224. PMID: 36939371, PMCID: PMC10338212, DOI: 10.1182/bloodadvances.2022009074.
- Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid NeoplasmsXie Z, Chen E, Mendez L, Komrokji R, Zeidan A. Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms. The Cancer Journal 2023, 29: 130-137. PMID: 37195768, DOI: 10.1097/ppo.0000000000000656.
- Mendez L, Patnaik M. Clonal Hematopoiesis: Origins and determinants of evolution. Leukemia Research 2023, 129: 107076. PMID: 37075557, DOI: 10.1016/j.leukres.2023.107076.
- VanOudenhove J, Halene S, Mendez L. Is it the time to integrate novel sequencing technologies into clinical practice? Current Opinion In Hematology 2022, 30: 70-77. PMID: 36602939, DOI: 10.1097/moh.0000000000000754.
- Daver N, Montesinos P, Aribi A, Marconi G, Altman J, Wang E, Roboz G, Burke P, Gaidano G, Walter R, Thomas X, Jeyakumar D, DeAngelo D, Erba H, Todisco E, Begna K, Advani A, Gastaud L, De La Fuente A, Curti A, Mendez L, Vyas P, Boissel N, Vey N, Recher C, Longval T, Platzbecker U, Kapp-Schwoerer S, Schliemann C, Konopleva M, Torres L, Sallman D, Marcucci G, Pemmaraju N, Martinelli G, Kantarjian H, Sloss C, Malcolm K, Zweidler-McKay P, Sweet K. Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML). Blood 2022, 140: 145-149. DOI: 10.1182/blood-2022-158030.
- Garcia J, Flamand Y, Penter L, Keng M, Tomlinson B, Mendez L, Koller P, Cullen N, Arihara Y, Pfaff K, Wolff J, Brunner A, Galinsky I, Bashey A, Antin J, Cutler C, Ho V, Jonas B, Luskin M, Wadleigh M, Winer E, Savell A, Leonard R, Robertson T, Davids M, Streicher H, Rodig S, Ritz J, Wu C, DeAngelo D, Neuberg D, Stone R, Soiffer R. Ipilimumab plus decitabine for patients with MDS or AML in post-transplant or transplant naïve settings. Blood 2022, 141: 1884-1888. PMID: 36332187, PMCID: PMC10122101, DOI: 10.1182/blood.2022017686.
- Daver N, Montesinos P, Aribi A, Martinelli G, Altman J, Wang E, Roboz G, Burke P, Gaidano G, Walter R, Thomas X, Jeyakumar D, DeAngelo D, Erba H, Todisco E, Begna K, Advani A, Gastaud L, de la Fuente A, Curti A, Mendez L, Vyas P, Boissel N, Vey N, Recher C, Longval T, Platzbecker U, Kapp-Schwörer S, Schliemann C, Konopleva M, Torres L, Sallman D, Marcucci G, Marconi G, Kantarjian H, Sloss C, Malcolm K, Zweidler-McKay P, Sweet K. AML-262 Pivekimab Sunirine (PVEK, IMGN632) Triplet With Azacitidine and Venetoclax Shows Broad Activity in Adverse Genetic Subsets of Relapsed/Refractory Acute Myeloid Leukemia and Reduced Infusion-Related Reactions. Clinical Lymphoma Myeloma & Leukemia 2022, 22: s231-s232. DOI: 10.1016/s2152-2650(22)01257-5.
- Daver N, Montesinos P, Aribi A, Martinelli G, Altman J, Wang E, Roboz G, Burke P, Gaidano G, Walter R, Thomas X, Jeyakumar D, DeAngelo D, Erba H, Todisco E, Begna K, Advani A, Gastaud L, de la Fuente A, Curti A, Mendez L, Vyas P, Boissel N, Vey N, Recher C, Longval T, Platzbecker U, Kapp-Schwörer S, Schliemann C, Konopleva M, Torres L, Sallman D, Marcucci G, Marconi G, Kantarjian H, Sloss C, Malcolm K, Zweidler-McKay P, Sweet K. Poster: AML-262 Pivekimab Sunirine (PVEK, IMGN632) Triplet With Azacitidine and Venetoclax Shows Broad Activity in Adverse Genetic Subsets of Relapsed/Refractory Acute Myeloid Leukemia and Reduced Infusion-Related Reactions. Clinical Lymphoma Myeloma & Leukemia 2022, 22: s132. DOI: 10.1016/s2152-2650(22)00792-3.
- Brunner A, Liu Y, Mendez L, Garcia J, Amrein P, Neuberg D, Dean E, Smith S, Stone R, Fathi A, Walter M, Graubert T, Jacoby M. P758: INHIBITION OF ATR WITH CERALASERTIB (AZD6738) FOR THE TREATMENT OF PROGRESSIVE OR RELAPSED MYELODYSPLASTIC SYNDROMES AND CHRONIC MYELOMONOCYTIC LEUKEMIA: A PHASE IB/II STUDY. HemaSphere 2022, 6: 653-654. DOI: 10.1097/01.hs9.0000845916.12740.98.
- Liegel J, Bindal P, Stone R, Soiffer R, Stroopinsky D, Cheloni G, Bisharat L, Torres D, Rahimian M, Yoo S, Logan E, Elavalakanar P, Banna H, Hauser J, Koshy A, Ho V, Romee R, Neuberg D, Liu Y, Mendez L, Dias A, Ebert B, Kufe D, Avigan D, Rosenblatt J. 158 Post-Transplant Vaccination with a Personalized Dendritic Cell/AML Fusion Cell Vaccine for Prevention of Relapse. Transplantation And Cellular Therapy 2022, 28: s129-s130. DOI: 10.1016/s2666-6367(22)00319-0.
- Liegel J, Bindal P, Stone R, Soiffer R, Stroopinsky D, Cheloni G, Bisharat L, Torres D, Rahimian M, Yoo S, Logan E, Elavalakanar P, Banna H, Hauser J, Koshy A, Romee R, Ho V, Neuberg D, Liu Y, Mendez L, Dias A, Ebert B, Kufe D, Avigan D, Rosenblatt J. Post-Transplant Vaccination with a Personalized Dendritic Cell/AML Fusion Cell Vaccine for Prevention of Relapse. Blood 2021, 138: 2830. DOI: 10.1182/blood-2021-154166.
- Luskin M, Stevenson K, Mendez L, Wang E, Wadleigh M, Garcia J, Stone R, An H, Hagopian E, Galinsky I, Rae L, Leonard R, DeAngelo D, Murakami M. A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for BCR-ABL1-Positive ALL in Adults. Blood 2021, 138: 2305. DOI: 10.1182/blood-2021-149225.
- Brunner A, Liu Y, Mendez L, Garcia J, Amrein P, Neuberg D, Dean E, Smith S, Stone R, Fathi A, Walter M, Graubert T, Jacoby M. Inhibition of ATR with AZD6738 (Ceralasertib) for the Treatment of Progressive or Relapsed Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: Safety and Preliminary Activity from a Phase Ib/II Study. Blood 2021, 138: 1521. DOI: 10.1182/blood-2021-147301.
- Daver N, Aribi A, Montesinos P, Roboz G, Wang E, Walter R, Jeyakumar D, DeAngelo D, Erba H, Advani A, Burke P, Martinelli G, Gastaud L, Thomas X, Altman J, Mendez L, de la Fuente A, Todisco E, Gaidano G, Curti A, Boissel N, Recher C, Schliemann C, Sloss C, Wang J, Malcolm K, Zweidler-McKay P, Sweet K. A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMGN632 As Monotherapy or in Combination with Venetoclax and Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia. Blood 2021, 138: 4440. DOI: 10.1182/blood-2021-146585.
- Daver N, Aribi A, Montesinos P, Roboz G, Wang E, Walter R, Jeyakumar D, DeAngelo D, Erba H, Advani A, Burke P, Martinelli G, Gastaud L, Thomas X, Altman J, Mendez L, de la Fuente A, Todisco E, Gaidano G, Curti A, Boissel N, Recher C, Schliemann C, Konopleva M, Sallman D, Torres L, Marcucci G, Kantarjian H, Sloss C, Malcolm K, Zweidler-McKay P, Sweet K. Safety and Efficacy from a Phase 1b/2 Study of IMGN632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia. Blood 2021, 138: 372. DOI: 10.1182/blood-2021-146503.
- Kukkula A, Ojala V, Mendez L, Sistonen L, Elenius K, Sundvall M. Therapeutic Potential of Targeting the SUMO Pathway in Cancer. Cancers 2021, 13: 4402. PMID: 34503213, PMCID: PMC8431684, DOI: 10.3390/cancers13174402.
- Sharda A, Bogue T, Barr A, Mendez L, Flaumenhaft R, Zwicker J. Circulating Protein Disulfide Isomerase Is Associated with Increased Risk of Thrombosis in JAK2-Mutated Myeloproliferative NeoplasmsPlasma PDI and Thrombosis in MPN. Clinical Cancer Research 2021, 27: 5708-5717. PMID: 34400417, PMCID: PMC9170286, DOI: 10.1158/1078-0432.ccr-21-1140.
- . VWF maturation and release are controlled by 2 regulators of Weibel-Palade body biogenesis: exocyst and BLOC-2. Blood 2020, 136: 2824-2837. PMID: 32614949, PMCID: PMC7731791, DOI: 10.1182/blood.2020005300.
- Nachmani D, Mendez L, Pandolfi P. Aberrant rRNA 2′-O-Methylation Causes Bone Marrow Failure and Defective Immune Function. Blood 2020, 136: 11-12. DOI: 10.1182/blood-2020-141809.
- Liegel J, Stone R, Soiffer R, Stroopinsky D, Bisharat L, Rahimian M, Logan E, Elavalakanar P, Ho V, Romee R, Neuberg D, Liu Y, Mendez L, Dias A, Bindal P, Koshy A, Orr S, Torres D, Cheloni G, Ebert B, Kufe D, Avigan D, Rosenblatt J. Vaccination with a Personalized Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in a Phase 1 Clinical Trial. Blood 2020, 136: 10. DOI: 10.1182/blood-2020-141634.
- Garcia J, Flamand Y, Tomlinson B, Keng M, Mendez L, Khaled S, Bashey A, Brunner A, Savell A, Neuberg D, Galinsky I, Luskin M, Steensma D, Wadleigh M, Winer E, Avigan D, Cullen N, Rodig S, Penter L, Lindsley R, Andrews S, Davids M, Wu C, Stone R, DeAngelo D, Soiffer R. Safety and Efficacy of Decitabine Plus Ipilimumab in Relapsed or Refractory MDS/AML in the Post-BMT or Transplant Naïve Settings. Blood 2020, 136: 15-17. DOI: 10.1182/blood-2020-136235.
- Brunner A, Blonquist T, DeAngelo D, McMasters M, Fell G, Hermance N, Winer E, Lindsley R, Hobbs G, Amrein P, Hock H, Steensma D, Garcia J, Luskin M, Stone R, Ballen K, Rosenblatt J, Avigan D, Nahas M, Mendez L, McAfee S, Moran J, Bergeron M, Foster J, Bertoli C, Manning A, McGregor K, Fishman K, Kuo F, Baltay M, Macrae M, Burke M, Behnan T, Wey M, Som T, Ramos A, Rae J, Lombardi Story J, Nelson N, Logan E, Connolly C, Neuberg D, Chen Y, Graubert T, Fathi A. Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. The Lancet Haematology 2019, 7: e122-e133. PMID: 31837959, PMCID: PMC10354959, DOI: 10.1016/s2352-3026(19)30203-0.
- Sharda A, Harrison J, Wilkie A, Fang C, Mendez L, Italiano J, Flaumenhaft R. VWF Exocytosis and Biogenesis of Weibel Palade Bodies in Endothelial Cells Are Differentially Controlled By Interactions between Bloc-2 and the Exocyst Complex. Blood 2019, 134: 8. DOI: 10.1182/blood-2019-127712.
- . The Interplay Between the Genetic and Immune Landscapes of AML: Mechanisms and Implications for Risk Stratification and Therapy. Frontiers In Oncology 2019, 9: 1162. PMID: 31781488, PMCID: PMC6856667, DOI: 10.3389/fonc.2019.01162.
- . Germline NPM1 mutations lead to altered rRNA 2′-O-methylation and cause dyskeratosis congenita. Nature Genetics 2019, 51: 1518-1529. PMID: 31570891, PMCID: PMC6858547, DOI: 10.1038/s41588-019-0502-z.
- . Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy. Cell Research 2019, 29: 446-459. PMID: 31024166, PMCID: PMC6796925, DOI: 10.1038/s41422-019-0162-7.
- Liegel J, Stroopinsky D, Mendez L, McMasters M, Ghiasuddin H, Rahimian M, Nahas M, Weinstock M, Jain S, Capelletti M, Bisharat L, Morin A, Orr S, Rosenblatt J, Kufe D, Avigan D. Ex-Vivo Stimulation with DC/AML Fusion Vaccine in the Presence of Cytokines Leads to an Activated T Cell Memory Phenotype and Enhanced Cytotoxicity with Potential for Use As an Adoptive Cellular Therapy. Blood 2018, 132: 2728. DOI: 10.1182/blood-2018-99-119996.
- . Deregulated PP1α phosphatase activity towards MAPK activation is antagonized by a tumor suppressive failsafe mechanism. Nature Communications 2018, 9: 159. PMID: 29335436, PMCID: PMC5768788, DOI: 10.1038/s41467-017-02272-y.
- . An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer. Nature Genetics 2018, 50: 206-218. PMID: 29335545, PMCID: PMC6714980, DOI: 10.1038/s41588-017-0027-2.
- . A non-cell-autonomous role for Pml in the maintenance of leukemia from the niche. Nature Communications 2018, 9: 66. PMID: 29302031, PMCID: PMC5754357, DOI: 10.1038/s41467-017-02427-x.
- Mendez L, Chen M, Pandolfi P. Molecular Genetics of APL. 2017, 41-53. DOI: 10.1007/978-3-319-64257-4_4.
- Pyzer AR, Stroopinsky D, Rosenblatt J, Anastasiadou E, Rajabi H, Washington A, Tagde A, Chu JH, Coll M, Jiao AL, Tsai LT, Tenen DE, Cole L, Palmer K, Ephraim A, Leaf RK, Nahas M, Apel A, Bar-Natan M, Jain S, McMasters M, Mendez L, Arnason J, Raby BA, Slack F, Kufe D, Avigan D. MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs. Leukemia 2017, 31: 2780-2790. PMID: 28555079, PMCID: PMC5791150, DOI: 10.1038/leu.2017.163.
- Pyzer A, Stroopinsky D, Rajabi H, Washington A, Tagde A, Coll M, Fung J, Bryant M, Cole L, Palmer K, Somaiya P, Karp Leaf R, Nahas M, Apel A, Jain S, McMasters M, Mendez L, Levine J, Joyce R, Arnason J, Pandolfi P, Kufe D, Rosenblatt J, Avigan D. MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia. Blood 2017, 129: 1791-1801. PMID: 28126925, PMCID: PMC5813734, DOI: 10.1182/blood-2016-07-730614.
- Mendez L, Sharda A, Zwicker J. Thrombophilia and Thrombocytopenia in the Pregnant Woman. 2017, 55-76. DOI: 10.1007/978-3-319-39328-5_4.
- Molecular Genetics of Acute Promyelocytic LeukemiaMendez LM, Chen M, Pandolfi PP. Molecular Genetics of Acute Promyelocytic Leukemia. In: Abla, Oussama, Lo Coco, Francesco, Sanz, Miguel A, editors. Acute Promyelocytic Leukemia. Springer 2018.
- Mendez L, Sharda A, Bodio K, Joyce R. PET/CT in lymphoma surveillance: A large single-center experience. Journal Of Clinical Oncology 2014, 32: 8569-8569. DOI: 10.1200/jco.2014.32.15_suppl.8569.
- Thrombophilia and Thrombocytopenia in the Pregnant WomanMendez LM, Sharda AV, Zwicker JI. Thrombophilia and Thrombocytopenia in the Pregnant Woman. In: Bernstein C, Takoudes T, editors. Medical Problems During Pregnancy. Springer: 2017
- Arnason J, Mendez L. Induction Therapy for Gamma-Heavy Chain Disease with Bortezomib and Dexamethasone: A Case Report. Blood 2012, 120: 5051. DOI: 10.1182/blood.v120.21.5051.5051.
- Cerchietti LC, Hatzi K, Caldas-Lopes E, Yang SN, Figueroa ME, Morin RD, Hirst M, Mendez L, Shaknovich R, Cole PA, Bhalla K, Gascoyne RD, Marra M, Chiosis G, Melnick A. BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy. J Clin Invest 2010, 120: 4569-82. PMID: 21041953, DOI: 10.1172/JCI42869.
- Mendez LM, Polo JM, Yu JJ, Krupski M, Ding BB, Melnick A, Ye BH. CtBP is an essential corepressor for BCL6 autoregulation. Mol Cell Biol 2008, 28: 2175-86. PMID: 18212045, DOI: 10.1128/MCB.01400-07.
- Ding BB, Yu JJ, Yu RY, Mendez LM, Shaknovich R, Zhang Y, Cattoretti G, Ye BH. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 2008, 111: 1515-23. PMID: 17951530, DOI: 10.1182/blood-2007-04-087734.
- Wang X, Ding BB, Mendez LM, Papetti M, Ye BH. Re: Torlakovic et al. PU.1 protein expression has a positive linear association with protein expression of germinal centre B cell genes including BCL-6, CD10, CD20 and CD22: identification of PU.1 putative binding sites in the BCL-6 promotor. J Pathol 2005;206:312-319. J Pathol 2006, 210: 130-1; author reply 132. PMID: 16841370, DOI: 10.1002/path.2031.
Departments and Programs
Locations
Hematology Program
Smilow Cancer Hospital at Yale New Haven
35 Park Street
New Haven, CT 06511
- Hematology ProgramSmilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511
Hematology Program
Smilow Cancer Hospital at Yale New Haven
35 Park Street
New Haven, CT 06511
- Hematology ProgramSmilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511